User:Mr. Ibrahem/Riociguat
 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Adempas |
| Other names | BAY 63-2521 |
| AHFS/Drugs.com | Monograph |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| Drug class | Soluble guanylate cyclase (sGC) stimulator[1] |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 94% |
| Protein binding | 95% |
| Metabolism | CYP1A1, CYP3A4, CYP2C8, CYP2J2 |
| Metabolites | N-desmethylriociguat (active), glucuronide (inactive) |
| Elimination half-life | 5–10 h |
| Excretion | 33–45% Kidney, 48–59% Bile duct |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C20H19FN8O2 |
| Molar mass | 422.424 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Riociguat, sold under the brand name Adempas is a medication used to treat two forms of pulmonary hypertension (PH): chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH).[1] It is a second line treatment.[1] It is taken by mouth.[1]
Common side effects include headache, upset stomach, nausea, and diarrhea.[1] Other side effects may include bleeding and low blood pressure.[1] Use in pregnancy may harm the baby.[1] It is a stimulator of soluble guanylate cyclase (sGC).[1]
Riociguat was approved for medical use in the United States in 2013.[1] In the United Kingdom it costs the NHS about £2,000 for 4 weeks as of 2021.[2] This amount in the United States costs about 9,500 USD.[3]
References[edit]
- ^ a b c d e f g h i j k "Riociguat Monograph for Professionals". Drugs.com. Archived from the original on 30 January 2021. Retrieved 17 October 2021.
- ^ a b BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 197. ISBN 978-0-85711-369-6.
{{cite book}}: CS1 maint: date format (link) - ^ "Adempas Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 10 August 2020. Retrieved 17 October 2021.